Evaluation of Dapagliflozin in the Treatment of Heart Failure

References

• Seferović PM , FragassoG, PetrieMet al. Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail.https://doi.org/10.1002/ejhf.1954 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Ponikowski P , VoorsAA, AnkerSDet al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J., 37(27), 2129–2200 (2016).
   PubMed Web of Science ®Google Scholar
• Meng W , EllsworthBA, NirschlAAet al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of Type 2 diabetes. J. Med. Chem., 51(5), 1145–1149 (2008).
   PubMed Web of Science ®Google Scholar
• Wright EM , LooDDF, HirayamaBA. Biology of human sodium glucose transporters. Physiol. Rev., 91(2), 733–794 (2011).
   PubMed Web of Science ®Google Scholar
• Kasahara M , MaedaM, HayashiS, MoriY, AbeT. A missense mutation in the Na(+)/glucose cotransporter gene SGLT1 in a patient with congenital glucose-galactose malabsorption: normal tracking but inactivation of the mutant protein. Biochim. Biophys. Acta, 7, 141–147 (2001).
   Google Scholar
• Turk E , ZabelB, MundlosS, DyerJ, WrightEM. Glucose/galactose malabsorption caused by a defect in the Na +/glucose cotransporter. Nature, 350(6316), 354–356 (1991).
   PubMed Web of Science ®Google Scholar
• van den Heuvel L , KarinA, WillemsenM, MonnensL. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum. Genet., 111(6), 544–547 (2002).
   PubMed Web of Science ®Google Scholar
• Santer R . Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J. Am. Soc. Nephrol., 14(11), 2873–2882 (2003).
   PubMed Web of Science ®Google Scholar
• Kim Y , BabuA. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of Type 2 diabetes. DMSO, 5, 313 (2012).
   Google Scholar
• DeFronzo RA , HompeschM, KasichayanulaSet al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with Type 2 diabetes. Diabetes Care, 36(10), 3169–3176 (2013).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , RazI, BonacaMPet al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N. Engl. J. Med., 380(4), 347–357 (2019).
   PubMed Web of Science ®Google Scholar
• Furtado RHM , BonacaMP, RazIet al. Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes mellitus and previous myocardial infarction: subanalysis from the DECLARE-TIMI 58 trial. Circulation, 139(22), 2516–2527 (2019).
   PubMed Web of Science ®Google Scholar
• McMurray JJV , SolomonSD, InzucchiSEet al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 381(21), 1995–2008 (2019).
   PubMed Web of Science ®Google Scholar
• Mullens W , DammanK, HarjolaV-Pet al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology: diuretics in heart failure. Eur. J. Heart Fail., 21(2), 137–155 (2019).
   PubMed Web of Science ®Google Scholar
• Sotirakos S , WheenP, SpiersJ, ArmstrongR. New pharmacotherapy for heart failure with reduced ejection fraction. Expert Rev. Cardiovasc. Ther., 18(7), 405–414 (2020).
   Web of Science ®Google Scholar
• Ehrenkranz JRL , LewisNG, RonaldKahn C, RothJ. Phlorizin: a review. Diabetes Metab. Res. Rev., 21(1), 31–38 (2005).
   PubMed Web of Science ®Google Scholar
• Washburn WN . Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus Type 2. J. Med. Chem., 52(7), 1785–1794 (2009).
   PubMed Web of Science ®Google Scholar
• Hummel CS , LuC, LiuJet al. Structural selectivity of human SGLT inhibitors. Am. J. Physiol. Cell Physiol., 302(2), C373–C382 (2012).
   PubMed Web of Science ®Google Scholar
• Komoroski B , VachharajaniN, FengY, LiL, KornhauserD, PfisterM. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther., 85(5), 513–519 (2009).
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ , de ZeeuwD, WieL, LeslieB, ListJ. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with Type 2 diabetes. Diabetes Obes. Metab., 15(9), 853–862 (2013).
   PubMed Web of Science ®Google Scholar
• Griffin M , RaoVS, Ivey-MirandaJet al. Empagliflozin in heart failure: diuretic and cardio-renal effects. Circulation(2020). https://doi.org/10.1161/CIRCULATIONAHA.120.045691
   Google Scholar
• Yurista SR , SilljéHHW, Oberdorf-MaassSUet al. Sodium–glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur. J. Heart Fail., 21(7), 862–873 (2019).
   PubMed Web of Science ®Google Scholar
• Garg V , VermaS, ConnellyK. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog. Cardiovasc. Dis., 62(4), 349–357 (2019).
   PubMed Web of Science ®Google Scholar
• Schwinger RH , BöhmM, KochAet al. The failing human heart is unable to use the Frank-Starling mechanism. Circ. Res., 74(5), 959–969 (1994).
   PubMed Web of Science ®Google Scholar
• Hwang I-C , ChoG-Y, YoonYEet al. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in Type 2 diabetic patients. Cardiovasc. Diabetol., 19(1), 69 (2020).
   PubMed Web of Science ®Google Scholar
• Brown AJM , GandyS, McCrimmonR, HoustonJG, StruthersAD, LangCC. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur. Heart J. doi: https://doi.org/10.1093/eurheartj/ehaa419 (2020) ( Epub ahead of print).
   Google Scholar
• Verma S , McMurrayJJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61(10), 2108–2117 (2018).
   PubMed Web of Science ®Google Scholar
• Hallow KM , HelmlingerG, GreasleyPJ, McMurrayJJV, BoultonDW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes. Metab., 20(3), 479–487 (2018).
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG , Requena-IbanezJA, SanAntonio Ret al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J. Am. Coll. Cardiol., 73(15), 1931–1944 (2019).
   PubMed Web of Science ®Google Scholar
• Li C , ZhangJ, XueMet al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc. Diabetol., 18(1), 15 (2019).
   PubMedGoogle Scholar
• Couselo-Seijas M , Agra-BermejoRM, FernándezALet al. High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment. Atherosclerosis, 292, 60–69 (2020).
   PubMed Web of Science ®Google Scholar
• Raj GM , WyawahareM. Dapagliflozin for heart failure – is it a class effect?Future Cardiol. doi: https://doi.org/10.2217/fca-2020-0087 (2020) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Brown E , RajeevSP, CuthbertsonDJ, WildingJPH. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes. Metab., 21(S2), 9–18 (2019).
   PubMedGoogle Scholar
• Zymliński R , BiegusJ, SokolskiMet al. Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion: lactates in acute heart failure. Eur. J. Heart Fail., 20(6), 1011–1018 (2018).
   PubMed Web of Science ®Google Scholar
• Packer M , CaliffRM, KonstamMAet al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation, 106(8), 920–926 (2002).
   PubMed Web of Science ®Google Scholar
• Uthman L , BaartscheerA, BleijlevensBet al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia, 61(3), 722–726 (2018).
   PubMed Web of Science ®Google Scholar
• Iborra-Egea O , Santiago-VacasE, YuristaSRet al. Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. JACC, 4(7), 831–840 (2019).
   Google Scholar
• Boulton DW , KasichayanulaS, KeungCFAet al. Simultaneous oral therapeutic and intravenous 14 C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin: absolute oral bioavailability of saxagliptin and dapagliflozin. Br. J. Clin. Pharmacol., 75(3), 763–768 (2013).
   PubMed Web of Science ®Google Scholar
• Obermeier M , YaoM, KhannaAet al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab. Dispos., 38(3), 405–414 (2010).
   PubMed Web of Science ®Google Scholar
• Kasichayanula S , LiuX, LaCretaF, GriffenSC, BoultonDW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin. Pharmacokinet., 53(1), 17–27 (2014).
   PubMed Web of Science ®Google Scholar
• Kasichayanula S , LiuX, ZhangW, PfisterM, LaCretaFP, BoultonDW. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin. Ther., 33(11), 1798–1808 (2011).
   PubMed Web of Science ®Google Scholar
• Kasichayanula S , LiuX, PeBenito Met al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with Type 2 diabetes mellitus: dapagliflozin treatment in renal impairment. Br. J. Clin. Pharmacol., 76(3), 432–444 (2013).
   PubMed Web of Science ®Google Scholar
• Januzzi JL , PrescottMF, ButlerJet al. Association of change in N-terminal pro–B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA, 322(11), 1085 (2019).
   PubMed Web of Science ®Google Scholar
• Kato ET , SilvermanMG, MosenzonOet al. Effect of dapagliflozin on heart failure and mortality in Type 2 diabetes mellitus. Circulation, 139(22), 2528–2536 (2019).
   PubMed Web of Science ®Google Scholar
• Zinman B , WannerC, LachinJMet al. Empagliflozin, cardiovascular outcomes and mortality in Type 2 diabetes. N. Engl. J. Med., 373(22), 2117–2128 (2015).
   PubMed Web of Science ®Google Scholar
• Nassif ME , WindsorSL, TangFet al. Dapagliflozin effects on biomarkers, symptoms and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation, 140(18), 1463–1476 (2019).
   PubMed Web of Science ®Google Scholar
• Carbone S , DixonDL. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with Type 2 diabetes mellitus. Cardiovasc. Diabetol., 18(1), 64 (2019).
   PubMedGoogle Scholar
• Perkovic V , JardineMJ, NealBet al. Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N. Engl. J. Med., 380(24), 2295–2306 (2019).
   PubMed Web of Science ®Google Scholar
• Neal B , PerkovicV, MahaffeyKWet al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N. Engl. J. Med., 377(7), 644–657 (2017).
   PubMed Web of Science ®Google Scholar
• Rådholm K , FigtreeG, PerkovicVet al. Canagliflozin and heart failure in Type 2 diabetes mellitus: results from the CANVAS Program. Circulation, 138(5), 458–468 (2018).
   PubMed Web of Science ®Google Scholar
• Zelniker TA , WiviottSD, RazIet al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in Type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, 393(10166), 31–39 (2019).
   PubMed Web of Science ®Google Scholar
• O'Riordan M . EMPEROR-reduced: empagliflozin cuts hospitalizations, CV mortality in HFrEF. https://www.tctmd.com/news/emperor-reduced-empagliflozin-cuts-hospitalizations-cv-mortality-hfref
   Google Scholar
• Zhang N , FengB, MaX, SunK, XuG, ZhouY. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovasc. Diabetol., 18(1), 107 (2019).
   PubMed Web of Science ®Google Scholar
• Jackson AM , DewanP, AnandISet al. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation (2020). https://doi.org/10.1161/CIRCULATIONAHA.120.047077
   Google Scholar
• Hsia DS , GroveO, CefaluWT. An update on SGLT2 inhibitors for the treatment of diabetes mellitus. 24(1), 73 (2018).
   Google Scholar
• Rosenstock J , FerranniniE. Euglycemic diabetic ketoacidosis: a predictable, detectable and preventable safety concern with SGLT2 inhibitors. Diabetes Care, 38(9), 1638–1642 (2015).
   PubMed Web of Science ®Google Scholar
• Monami M , NardiniC, MannucciE. Efficacy and safety of sodium glucose co-transport-2 inhibitors in Type 2 diabetes: a meta-analysis of randomized clinical trials: SGLT-2 inhibitors in Type 2 diabetes. Diabetes Obes. Metab., 16(5), 457–466 (2014).
   PubMed Web of Science ®Google Scholar
• Drugs.com . Forxiga [Internet]. https://www.drugs.com/international/forxiga.html
   Google Scholar
• U.S. Food and Drug Administration . Highlights of prescribing information [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202293s021lbl.pdf
   Google Scholar
• U.S. Food and Drug Administration . FDA approves new treatment for a type of heart failure [Internet]. (2020). https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure
   Google Scholar